Patients are our first priority at Assembly Biosciences. Through our work, we know what it means to live with illnesses like chronic hepatitis B virus (HBV). That is why we are focused on delivering curative treatment options for HBV patients. For the same reason, we are also exploring how we can leverage the human gut microbiome and our patented delivery technology, GEMICELĀ®, to treat patients facing digestive diseases and other conditions. The needs of patients guide us and provide direction for our work. From our people to our research, technologies and product platforms, we never lose sight of our mission: to deliver innovative and curative therapies.

Through our work, we have seen what it means to live with illnesses like chronic Hepatitis B virus (HBV) and that is why we are focused on delivering curative treatment options for HBV patients. For the same reason, we are also exploring how we can leverage the human microbiome, which is comprised of the bacteria that lives in the gut, and our patented delivery technology, GEMICEL®, to treat a range of diseases in new ways and bring new options to patients facing digestive diseases and other conditions. We have seen the discouragement, frustration, and distress that patients face. We started our company to change that.

Patients already face a difficult road, navigating the complexities of their diseases and evaluating their treatment options, while trying to balance everything else in their lives. Assembly Biosciences is committed to guiding and supporting them throughout their journey to manage and potentially overcome their diseases.